Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort

Siegel, 2017, Cancer Statistics, 2017, CA Cancer J Clin, 67, 7, 10.3322/caac.21387 Resnick, 2013, Long-term functional outcomes after treatment for localised prostate cancer, N Engl J Med, 368, 438, 10.1056/NEJMoa1209978 van der Poel, 2018, Focal therapy in primary localised prostate cancer: the European Association of Urology position in 2018, Eur Urol, 74, 84, 10.1016/j.eururo.2018.01.001 Valerio, 2017, New and established technology in focal ablation of the prostate: a systematic review, Eur Urol, 71, 177, 10.1016/j.eururo.2016.08.044 Azzouzi, 2017, Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer; an open-label, phase 3, randomised controlled trial, Lancet Oncol, 18, 181, 10.1016/S1470-2045(16)30661-1 Ganzer, 2018, Prospective multicentre phase II study on focal therapy (hemiablation) of the prostate with high intensity focused ultrasound, J Urol, 199, 983, 10.1016/j.juro.2017.10.033 Guillaumier, 2018, A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer, Eur Urol, 74, 422, 10.1016/j.eururo.2018.06.006 Scheltema, 2017, Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project, World J Urol, 35, 695, 10.1007/s00345-016-1932-1 Thompson JE, Sridhar AN, Tan WS, et al. Pathologic findings and MRI concordance at salvage radical prostatectomy for local recurrence following partial ablation using high-intensity focused ultrasound. J Urol. In press. https://doi.org/10.1097/JU.0000000000000135. Dickinson, 2016, Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localised prostate cancer, Urol Oncol Semin Orig Investig, 35, 30.e9 Onik, 2007, Irreversible electroporation: implications for prostate ablation, Technol Cancer Res Treat, 6, 295, 10.1177/153303460700600405 van den Bos, 2018, Focal irreversible electroporation as primary treatment for localised prostate cancer, BJU Int, 121, 716, 10.1111/bju.13983 Le Nobin, 2015, Image guided focal therapy for magnetic resonance imaging visible prostate cancer: defining a 3-dimensional treatment margin based on magnetic resonance imaging histology co-registration analysis, J Urol, 194, 364, 10.1016/j.juro.2015.02.080 Scheltema MJ, Chang JI, van den Bos W, et al. Preliminary diagnostic accuracy of multiparametric magnetic resonance imaging to detect residual prostate cancer following focal therapy with irreversible electroporation. Eur Urol Focus. In press. doi.org/10.1016/j.euf.2017.10.007. van den Bos, 2016, Histopathological outcomes after irreversible electroporation for prostate cancer: results of an ablate and resect study, J Urol, 196, 5523, 10.1016/j.juro.2016.02.2977 Murray, 2016, Pilot study to assess safety and clinical outcomes of irreversible electroporation for partial gland ablation in men with prostate cancer, J Urol, 196, 883, 10.1016/j.juro.2016.02.2986 Valerio, 2017, Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localised prostate cancer, J Urol, 197, 647, 10.1016/j.juro.2016.09.091 Shah TT, Peters M, Eldred-Evans D, et al. Early-Medium-Term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.12.030. Muller, 2015, Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project, World J Urol, 33, 1503, 10.1007/s00345-014-1475-2 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localised prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 King, 2012, Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer, Br J Cancer, 106, 638, 10.1038/bjc.2011.552